Avid Radiopharmaceuticals, Inc. (Avid RP) is a product-focused molecular imaging company developing novel diagnostic agents to enable early diagnosis, treatment selection and therapeutic monitoring of serious diseases. The company is a pioneer in clinical development of agents for detecting and monitoring Alzheimer's disease, and its lead radiolabeled compounds are being developed to enable physicians to diagnose Alzheimer's in real-time and to allow Alzheimer's researchers to evaluate the many drug candidates targeting amyloid plaque build-up. Avid's technology can be used with a variety of imaging technologies such as PET and SPECT scanning and has already been tested in pilot human studies.